Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Closes Inpharmatica Acquisition

NEW YORK (GenomeWeb News) - Galapagos today said it has issued a final tranche of 113,378 shares to close its acquisition of informatics firm Inpharmatica.
 
Galapagos announced in December that it was acquiring the UK-based company in a share exchange over three tranches worth as much as €19.1 million ($25.4 million).
 
Galapagos plans to fold Inpharmatica into its drug discovery services business, BioFocus DPI.
 
Under the deal, Inpharmatica contributed C Preference shares to Galapagos in exchange for a total of 2,165,532 newly issued Galapagos shares.
 
A first tranche of 623,582 Galapagos shares was issued in December, and another trance of 613,270 shares was issued in April. The final tranche was issued yesterday. 
 
In the end, Galapagos issued 815,302 fewer shares than the maximum the agreement allowed, at a value of around €7 million, because Inpharmatica failed to meet certain milestones laid out in the purchase agreement.
  
Galapagos now has 20,592,766 shares outstanding, at a value of €111.9 million, the company said. 

Filed under

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.